CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER Drug Patent Profile

When do Cefotetan And Dextrose In Duplex Container patents expire, and when can generic versions of Cefotetan And Dextrose In Duplex Container launch?

Cefotetan And Dextrose In Duplex Container is a drug marketed by B Braun and is included in one NDA.

The generic ingredient in CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER is cefotetan disodium. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the cefotetan disodium profile page.

Summary for CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	22
Patent Applications:	1,629
DailyMed Link:	CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER at DailyMed

US Patents and Regulatory Information for CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER	cefotetan disodium	INJECTABLE;INJECTION	065430-001	Aug 9, 2007		DISCN	Yes	No
B Braun	CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER	cefotetan disodium	INJECTABLE;INJECTION	065430-002	Aug 9, 2007		DISCN	Yes	No

Cefotetan and Dextrose in DUPLEX Container: Market Dynamics, Patent Position, and Financial Trajectory

Last updated: August 31, 2026

Cefotetan and Dextrose Injection in the DUPLEX Container is a mature, hospital-only generic injectable with limited patent protection and low standalone revenue visibility. Its commercial value comes from sterile-manufacturing capacity, hospital contracts, supply reliability, and the operational advantage of Baxter’s dual-chamber DUPLEX delivery system rather than from exclusivity or clinical differentiation. Product-level sales are not separately disclosed in Baxter’s public financial reports, so the financial trajectory must be assessed through market structure, procurement dynamics, supply conditions, and the broader performance of generic injectable operations.

What is Cefotetan and Dextrose in the DUPLEX Container?

Cefotetan and Dextrose Injection is an intravenous formulation containing cefotetan disodium, a second-generation cephamycin antibacterial, in a dextrose solution. The DUPLEX Container is a dual-chamber intravenous system that separates the drug powder from the diluent until activation before administration.

The product is used for susceptible bacterial infections and perioperative prophylaxis. Its label includes indications involving gynecologic, intra-abdominal, skin and skin-structure, urinary tract, and lower respiratory tract infections, subject to the labeled organism and susceptibility requirements.[1]

The U.S. product is associated with Baxter Healthcare Corporation and is supplied in premixed configurations generally centered on 1-gram and 2-gram cefotetan strengths. The commercial proposition is operational:

• No conventional bedside reconstitution from a vial is required.
• The dual-chamber container reduces preparation steps.
• The product can be stocked in hospital pharmacies and procedural areas.
• The format supports standardized dosing and closed-system handling.

The product competes with conventional cefotetan vials, other cephalosporins, and alternative surgical prophylaxis regimens.

What is the FDA regulatory status of Cefotetan and Dextrose in DUPLEX Container?

Cefotetan and Dextrose Injection is an approved prescription generic injectable. It is not a biologic and does not follow the biosimilar pathway. The relevant regulatory framework is the abbreviated new drug application, or ANDA, for a therapeutically equivalent generic product, although the specific regulatory history can include legacy applications and product-specific approvals.

The product is subject to:

• FDA current good manufacturing practice requirements.
• Sterile injectable manufacturing controls.
• Container-closure and stability requirements.
• Labeling requirements for cefotetan, dextrose, renal dosing, hypersensitivity, and antimicrobial-associated adverse events.
• FDA reporting requirements for manufacturing deviations, recalls, and supply interruptions.

The product does not have an active new-drug exclusivity profile comparable with a recently approved branded medicine. Cefotetan has been commercially available for decades, and the relevant compound and use patents expired long before the current generic market.

What patents protect Cefotetan and Dextrose in the DUPLEX Container?

The product has little or no meaningful remaining compound patent protection. Cefotetan is an old antibacterial agent, and its basic composition-of-matter exclusivity has expired.

The commercially relevant intellectual-property position is narrower:

IP category	Current commercial relevance
Cefotetan compound patent	Expired
Core antibacterial indication patents	Expired or commercially immaterial
Dextrose solution technology	Generally not product-specific exclusivity
DUPLEX container design	Potentially protected at the platform or system level, but not equivalent to a cefotetan monopoly
Manufacturing process	May contain confidential know-how and facility-specific controls
Product formulation	Limited ability to prevent substitution by vial-based cefotetan
Method-of-use patents	No material current barrier to generic cefotetan use identified
Regulatory exclusivity	No meaningful current exclusivity period

A container patent or proprietary delivery-system right can support differentiation without blocking a competing manufacturer from selling cefotetan in a vial, premixed bag, or another dual-chamber system. The practical competitive barrier is therefore manufacturing execution, not exclusionary patent scope.

What is the Orange Book status of Cefotetan and Dextrose in the DUPLEX Container?

The Orange Book is primarily relevant to approved prescription drugs with listed patents and therapeutic-equivalence determinations. A mature generic injectable such as cefotetan and dextrose in a DUPLEX Container does not generally present an active Orange Book patent estate that would delay generic entry.

The expected Orange Book profile is:

• No significant unexpired product patent blocking generic competition.
• No meaningful pediatric exclusivity.
• No current five-year new chemical entity exclusivity.
• No commercially relevant three-year clinical-investigation exclusivity.
• Therapeutic-equivalence issues, if any, centered on the specific approved product and dosage form rather than a branded patent dispute.

When does Cefotetan and Dextrose lose exclusivity?

Cefotetan lost core exclusivity many years ago. The product is already in the post-exclusivity generic phase.

Milestone	Status
Original cefotetan approval	Historical, decades old
Compound patent protection	Expired
New chemical entity exclusivity	Expired
Generic competition	Established
Current market phase	Mature injectable generic
Remaining exclusivity driver	Delivery-system differentiation and supply contracts, not drug patents

Paragraph IV challenges are therefore not the central competitive issue. A Paragraph IV certification is most relevant when a listed drug has an unexpired patent in the Orange Book. For this product, commercial competition is more likely to arise through ANDA approvals, contract wins, manufacturing transfers, shortages, and hospital formulary decisions.

How strong is the patent estate for the DUPLEX Container product?

The patent estate is weak as a drug-specific barrier and potentially stronger as a platform-level manufacturing and packaging asset.

The DUPLEX system can create three types of defensibility:

1. A proprietary or difficult-to-replicate dual-chamber container.
2. Validated sterile filling and sealing processes.
3. Operational integration with Baxter’s hospital supply and distribution infrastructure.

Those advantages do not prevent substitution with:

• Cefotetan vials.
• Generic cefotetan products from other suppliers.
• Alternative cephalosporins.
• Different premixed or ready-to-use IV systems.

The result is a low-to-moderate commercial moat, with the strongest protection in procurement convenience and supply reliability. The moat is not comparable with an active pharmaceutical patent, a biologic manufacturing platform, or a patented long-acting formulation.

What market dynamics affect Cefotetan and Dextrose in the DUPLEX Container?

Hospital purchasing dominates demand

The product is sold primarily through hospitals, health systems, group purchasing organizations, wholesalers, and institutional pharmacy channels. Retail pharmacy demand is negligible.

Hospital buyers evaluate:

• Contract price.
• Availability and allocation history.
• Shelf life.
• Product presentation.
• Preparation labor.
• Medication-error risk.
• Compatibility with pharmacy automation.
• Vendor diversification requirements.
• Shortage exposure.

A dual-chamber container can command a price premium over a conventional vial when it reduces pharmacy labor or supports operating-room workflow. That premium is constrained by generic substitution and hospital budget pressure.

Cefotetan occupies a narrow therapeutic position

Cefotetan is not a high-growth antibiotic. Many hospitals use other cephalosporins or combination regimens depending on local resistance patterns, surgical protocols, stewardship policies, and clinical guidelines.

Demand is supported by:

• Established clinical familiarity.
• Surgical prophylaxis use.
• Need for broad anaerobic and gram-negative coverage in selected settings.
• Hospital protocols that retain cefotetan as an available option.
• Periodic shortages affecting alternative injectable antibiotics.

Demand is limited by:

• Antimicrobial stewardship.
• Resistance concerns.
• Availability of lower-cost alternatives.
• Narrower institutional formularies.
• Declining use of older antibiotics in some settings.

Sterile injectables remain supply-sensitive

The market has relatively few qualified sterile injectable manufacturers compared with oral generics. This creates recurring exposure to:

• Manufacturing deviations.
• Fill-finish interruptions.
• Active pharmaceutical ingredient constraints.
• Container-component shortages.
• Inspection findings.
• Product discontinuations.
• Hospital stockpiling during shortage periods.

For a mature injectable, a temporary competitor shortage can materially increase orders. The effect is usually episodic rather than a durable increase in market size.

What is the financial trajectory for Cefotetan and Dextrose in the DUPLEX Container?

Product-level revenue is not separately reported by Baxter. Public company reporting generally aggregates products within broader categories such as pharmaceuticals, infusion therapies, hospital products, or medical delivery systems.[2] No reliable public figure establishes annual sales, gross margin, or EBITDA for this individual product.

The likely financial trajectory is as follows:

Period	Revenue direction	Main drivers
Launch and early adoption	Rising	DUPLEX differentiation, hospital conversion, contract placement
Mature branded-generic period	Stable to moderately declining	Generic price erosion and established utilization
Shortage-driven periods	Volatile upside	Competitor outages and emergency purchasing
Normalized mature period	Flat to declining	Lower antibiotic use, tender pricing, substitution
Long-term outlook	Low-growth, cash-generative if supplied efficiently	Manufacturing scale and procurement retention

The product’s economic profile is likely defined by modest revenue, recurring institutional demand, and relatively low selling expenses. Margin depends heavily on plant utilization, component costs, labor, quality overhead, and contract pricing. A dual-chamber container is more expensive to manufacture than a basic vial because it requires specialized packaging, validated chamber separation, activation performance, and additional quality controls.

A key financial risk is volume loss without an equivalent reduction in fixed manufacturing costs. If hospital contracts migrate to lower-priced vials or competing premix systems, the product can experience margin compression faster than revenue decline.

Which companies compete with Cefotetan and Dextrose in the DUPLEX Container?

The competitive set includes both direct and indirect alternatives.

Direct competition

Direct competitors include manufacturers offering cefotetan injection in conventional vial or premixed presentations. The relevant competitors can change over time because generic injectable suppliers enter and exit markets based on profitability, FDA compliance, and supply economics.

Indirect competition

The broader clinical alternatives include:

• Cefazolin.
• Cefoxitin.
• Cefepime.
• Ceftriaxone.
• Ampicillin-sulbactam.
• Piperacillin-tazobactam.
• Metronidazole-containing regimens.
• Institution-specific surgical prophylaxis protocols.

These products may compete for the same hospital budget or treatment pathway even when they are not direct pharmaceutical equivalents.

What generic entry risks exist for Cefotetan and Dextrose in the DUPLEX Container?

Generic entry risk is already realized because cefotetan is an established generic. The relevant risk is further supplier competition, not the first generic launch.

Price erosion risk

Additional vial suppliers can pressure contract prices. Hospitals may accept the lower-cost vial where pharmacy labor and preparation risk are manageable.

Substitution risk

A hospital can remove the DUPLEX product without changing to another cefotetan supplier. It can instead use an alternative antibiotic or a different dosage form.

Contract concentration risk

Loss of a major group-purchasing or health-system contract can reduce volume quickly. Institutional products often have concentrated purchasing channels.

Supply interruption risk

A manufacturing interruption can cause lost sales, regulatory scrutiny, and replacement by competitors. The same interruption can temporarily increase demand if competitors are constrained.

Container replication risk

A competing dual-chamber system could weaken the product’s convenience premium. The strongest defense is validated manufacturing scale, distribution, and customer integration.

What patent litigation or settlement agreements affect the product?

No major active patent litigation or settlement structure is central to the current commercial profile of cefotetan and dextrose in the DUPLEX Container. The product is a mature generic injectable rather than a newly launched branded medicine facing Paragraph IV litigation.

The more relevant legal and regulatory exposures are:

• Product-liability claims.
• FDA manufacturing enforcement.
• Recall obligations.
• Supply-contract disputes.
• Antitrust scrutiny involving generic pricing or allocation.
• Hospital purchasing disputes.
• Intellectual-property disputes involving container technology, if asserted.

No product-specific licensing transaction or major settlement is a publicly established driver of the current market.

How does Cefotetan and Dextrose in the DUPLEX Container compare with conventional cefotetan vials?

Attribute	DUPLEX Container	Conventional vial
Preparation	Dual-chamber activation and mixing	Reconstitution by pharmacy or clinical staff
Packaging complexity	High	Lower
Labor burden	Potentially lower	Higher
Unit manufacturing cost	Likely higher	Typically lower
Storage and handling	Institutional cold-chain and label controls apply	Standard vial procedures
Patent differentiation	Container-related	Minimal
Hospital value proposition	Workflow and safety	Price and flexibility
Substitution risk	High	High
Commercial moat	Moderate operational differentiation	Low

The DUPLEX product is most competitive where hospitals value ready preparation, standardized administration, and reduced compounding work. It is less competitive where procurement teams prioritize lowest acquisition cost.

What are the geographic coverage and manufacturing barriers?

The principal commercial market is the United States hospital sector. Geographic expansion is constrained by country-specific regulatory approvals, injectable manufacturing registrations, labeling, reimbursement systems, and local procurement structures.

Manufacturing barriers include:

• Sterile compounding validation.
• Dual-chamber container supply.
• Aseptic filling capacity.
• Stability data.
• Container activation testing.
• Microbial and particulate controls.
• Drug-device combination quality systems.
• FDA inspection compliance.
• Reliable cefotetan API sourcing.

These barriers support supply continuity but do not create durable monopoly economics. Competitors with qualified sterile facilities and compatible packaging can enter if expected contract prices justify the investment.

What is the outlook for Cefotetan and Dextrose in the DUPLEX Container?

The outlook is mature and defensive rather than growth-oriented. The product should be evaluated as a hospital supply and manufacturing asset with limited patent risk and meaningful operational risk.

The most likely base case is:

• Stable or gradually declining underlying demand.
• Periodic volume spikes during competitor shortages.
• Continued price pressure in hospital tenders.
• Value concentrated in the DUPLEX presentation and Baxter distribution.
• No meaningful patent-driven price protection.
• Revenue volatility tied to contracts, supply continuity, and antibiotic substitution.

Upside would require sustained competitor shortages, expanded hospital adoption of dual-chamber systems, or favorable contract renewals. Downside would come from lower-cost vial substitution, loss of a major purchasing agreement, quality-related interruption, or reduced use of cefotetan in hospital protocols.

Key Takeaways

• Cefotetan and Dextrose in the DUPLEX Container is a mature generic intravenous product associated with Baxter’s dual-chamber delivery platform.
• Core cefotetan patent and regulatory exclusivity have expired.
• Paragraph IV litigation is not the primary market issue.
• The relevant commercial advantage is preparation convenience, not drug exclusivity.
• Product-level revenue is not separately disclosed in Baxter’s public filings.
• Financial performance is likely modest, recurring, and sensitive to hospital contracts, sterile manufacturing costs, and shortages.
• Direct competition comes from cefotetan vials and other injectable suppliers.
• Indirect competition comes from alternative cephalosporins, beta-lactam combinations, and hospital protocol changes.
• The principal barriers are sterile manufacturing, container technology, quality compliance, and distribution scale.
• Long-term prospects are low growth with episodic upside during injectable antibiotic shortages.

FAQs

Is Cefotetan and Dextrose in the DUPLEX Container a branded drug?

It is a generic injectable product sold in Baxter’s DUPLEX delivery system. The container presentation provides product differentiation, but cefotetan itself is an established generic antibiotic.

Does the product have a biosimilar competitor?

No. Cefotetan is a small-molecule antibacterial, not a biologic. Competing products enter through generic-drug pathways rather than biosimilar applications.

Can a hospital substitute a cefotetan vial for the DUPLEX product?

Potentially, subject to the hospital formulary, pharmacy procedures, approved labeling, dosing requirements, and purchasing protocols. The vial is a practical substitute when the institution accepts the additional preparation step.

Is the DUPLEX Container protected by patents?

The delivery platform may have had or may retain platform-level intellectual-property rights, but those rights do not provide compound exclusivity for cefotetan or prevent competing cefotetan products in other presentations.

Is cefotetan and dextrose injection exposed to antibiotic shortages?

Yes. The product is exposed to the same sterile-injectable supply risks affecting other hospital antibiotics. A shortage can increase short-term demand, but it can also create service and regulatory risk for the manufacturer.

References

1. U.S. Food and Drug Administration. (n.d.). Cefotetan and dextrose injection, USP, in DUPLEX Container prescribing information. FDA labeling database.

2. Baxter International Inc. (2024). 2023 annual report. Baxter International Inc.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Drug shortages database. FDA Center for Drug Evaluation and Research.

5. National Library of Medicine. (n.d.). Cefotetan and dextrose injection product information. DailyMed.